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Poliovirus genomes encoding the complete gag or env surface gene of the simian immunodeficiency virus SIVsmm PBj14
(SIV-PBj14) were constructed. The in vitro-transcribed RNA from these genomes, referred to as replicons, have the capacity
for self-replication when transfected into tissue culture cells. Serial passage of the replicons containing the SIV-PBj14 gag
or SIV-PBj14 env (SU) genes with a recombinant vaccinia virus, VV-P1, which provides P1 in trans, resulted in the encapsida-
tion of these replicons. Infection of cells with the encapsidated replicons that encode gag, referred to as vIC-SIV-PBj14
Gag, resulted in the production of a 55-kDa protein that was released from the infected cells. Using a sucrose density-
gradient analysis, the protein was found to sediment at a density consistent with that of a virus-like particle. Infection of
cells with a replicon that encodes the env SU gene, referred to as vIC-SIV-PBj14 SU, resulted in the production of two SIV-
PBj14 envelope-related intracellular proteins. One of these proteins had a molecular mass consistent with that of the
unglycosylated SIV-PBj14 SU protein (63 kDa); the second protein had a higher molecular mass (160 kDa). Characterization
of this larger protein revealed that it was glycosylated and possibly represented a dimer of the SU protein. A pulse–chase
analysis of cells infected with vIC-SIV-PBj14 SU demonstrated that a 110- to 130-kDa protein was released, which is
consistent with the molecular mass of the SIV-PBj14 SU protein. The results of these studies demonstrate that poliovirus
replicons can be used to express foreign proteins, including glycoproteins, which retain many of the physical features of
the native protein. q 1996 Academic Press, Inc.
INTRODUCTION viruses results in processing of P1 and assembly of capsid
proteins into subviral intermediates (Ansardi et al., 1991).
The poliovirus genome is a single-stranded RNA mole-
The vaccinia virus that expresses the poliovirus P1 protein,
cule consisting of 7500 bases (Kitamura et al., 1981). The
VV-P1, can also be used to complement poliovirus ge-
coding region of the poliovirus genome has been divided
nomes in which the capsid genes have been deleted (An-
into three regions, designated as P1, P2, and P3 (Koch
sardi et al., 1993). The ability to complement defective ge-
and Koch, 1985; Rueckert and Wimmer, 1984). The P1
nomes with P1 provided in trans from VV-P1 and to pro-
region encodes the viral capsid proteins VP0, VP3, and
duce infectious stocks suggested that poliovirus might be
VP1 while the proteins of the P2 and P3 regions encode
used as an expression system. To facilitate this possibility,
the nonstructural proteins that are required for poliovirus
RNA genomes that contain regions of the HIV-1 gag, pol,
replication (Koch and Koch, 1985; Rueckert and Wimmer, and env genes substituted for the VP3 and VP1 genes in
1984). Initial expression of the poliovirus genome results poliovirus were generated (Choi et al., 1991). When these
in the synthesis of a long polyprotein which is subse- RNA genomes, referred to as replicons, were transfected
quently processed at a specific tyrosine–glycine amino into cells, they replicated and expressed the HIV protein
acid pair by 2Apro to release the P1 protein (Harris et al., as a fusion protein with the remaining poliovirus P1 capsid
1990; Toyoda et al., 1986). The P1 protein is processed proteins. More importantly, transfection of these RNA ge-
by the viral protease 3Cpro as a fusion protein with the nomes into cells previously infected with VV-P1 resulted
viral RNA polymerase 3Dpol, referred to as 3CD (Jore et al., in encapsidation (Porter et al., 1993). The availability of
1988; Ypma-Wong et al., 1988; Ypma-Wong and Semler, encapsidated poliovirus replicons that express foreign
1987). Remaining cleavages of the P2 and P3 region genes has prompted an evaluation of the immunogenicity
proteins are carried out by 3Cpro (Harris et al., 1990). of these replicons. Replicons that express portions of the
Previous studies from this laboratory demonstrated that HIV-1 gag or env genes or carcinoembryonic antigen did
independent expression in infected cells of the P1 precur- elicit immune responses when given to animals (Ansardi
sor protein and 3CD polyprotein by recombinant vaccinia et al., 1994b; Moldoveanu et al., 1995). These studies also
included immunization of a single pig-tailed macaque with
a replicon expressing HIV-1 Gag; this animal produced1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (205) 934-1580. antibodies to both poliovirus and to HIV-1 Gag, the latter
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after boosting with purified Gag antigen (Morrow et al., tissue culture media and supplements were purchased
1994). Since HIV-1 does not cause disease in pig-tailed from Gibco BRL. The 35S-Translabel (methionine–cys-
macaques, the relevant antigens from a different lentivirus teine) and methionine–cysteine-free Dulbecco modified
should be expressed to evaluate whether replicons can Eagle’s medium (DMEM) were purchased from ICN Bio-
induce protective immune responses. Because of the close chemicals. Restriction enzymes were obtained from New
genetic relationship between isolates of HIV and the sim- England Biolabs. The synthetic DNA primers were pur-
ian immunodeficiency virus (SIV) and the similarities in chased from Cruachem, Fisher Company. Taq polymer-
diseases caused by these lentiviruses, infection of ma- ase and reagents for the polymerase chain reaction
caques with SIV is the best model system for studying (PCR) were purchased from Gibco BRL. Enzymes used
various aspects related to HIV infection of humans. One for deglycosylation reactions were obtained from Boeh-
pathogenic isolate, SIVsmmPBj14 (SIV-PBj14), induces rapid ringer Mannheim.
onset of a well-characterized acute disease syndrome in
pig-tailed macaques after infection by either parenteral or Tissue culture cells and viruses
mucosal routes (Fultz et al., 1989, 1995; Novembre et al.,
HeLa T4 and BSC-40 cells were grown in DMEM sup-1993; Schwiebert and Fultz, 1994). In addition, infectious
plemented with 10% fetal bovine serum (complete me-biological and molecular clones that reproduce the acute
dium). Poliovirus type 1 Mahoney was derived from trans-pathogenicity of SIV-PBj14 have been generated (Dew-
fection of BSC-40 cells with an infectious cDNA clonehurst et al., 1990; Fultz et al., 1989; Novembre et al., 1993).
obtained from B. Semler, University of California at IrvineThus, this SIV–macaque model is useful for evaluating
(Semler et al., 1984). The recombinant vaccinia virus, VV-novel vaccine approaches for induction of mucosal im-
P1, which expresses the poliovirus P1 capsid precursormune responses and for efficacy in the prevention of both
protein upon infection, was described previously (An-infection and disease following exposure to virus by multi-
sardi et al., 1991). The recombinant vaccinia virus, VVK1ple routes.
(Karacostas et al., 1989), antisera to HIV-1 p25/24 GagIn recent studies, we found that the entire P1 region
(Steimer et al., 1986), and unglycosylated HIV-1 gp120can be deleted without affecting the replication capacity
were obtained from the AIDS Research and Referenceof the replicons. Substitution of P1 with the complete
Reagent Program. The recombinant vaccinia virus thatHIV-1 gag gene resulted in a replicon that expressed
expresses HIV-1 gp160 (VV-gp160) was provided by He-Pr55gag upon infection (Porter et al., 1995). In this same
lene Bernstein (Owens and Compans, 1990).study, we demonstrated that replicons with the VP4 cod-
ing region can be grown to higher levels than replicons
Construction of replicons containing the SIV-PBj14with a deletion of VP4. Since the foreign protein was
gag and env SU genesexpressed as a fusion protein with VP4, a cleavage site
for 2Apro was engineered at the carboxy terminus of VP4 The plasmid containing the poliovirus cDNA in which
to facilitate proteolytic processing by 2Apro in trans to SIV-PBj14 gag and env SU genes were cloned was de-
release the foreign protein with minimal amino acid scribed previously, with the exception that an XhoI re-
changes at its amino terminus (Porter et al., 1995). To striction site was substituted for the SacI restriction site
date though, the only report of using this replicon has to facilitate cloning the SIV-PBj14 genes (Ansardi et al.,
been with the HIV-1 Gag protein and it is not established 1994; Porter et al., 1995) (Fig. 1). Using the DNA primers
that other foreign genes could be expressed with this 5*-G-TGG-GAG-ATG-GGC-CTC-GAG-AAC-TCC-GTC-TTG-
replicon. In addition, the expression of glycoproteins us- 3* (5* oligomer) and 5*-TGT-AGG-CCG-GTT-AAC-TTG-
ing this replicon has not been reported; this is an im- GTC-TTC-3* (3* oligomer), nucleotides 822–2364 from
portant point because previous studies have suggested the plasmid pSIVsmm-PBj14-1.9 (Dewhurst et al., 1990) were
that poliovirus-based vectors could not be used to ex- amplified by PCR to yield the complete SIV-PBj14 gag
press glycoproteins (Lu et al., 1995). To address these gene. The complete SIV-PBj env SU gene was amplified
questions, this report describes the construction and from nucleotide 6357 to 7952 of the same plasmid using
characterization of poliovirus replicons that encode the the DNA primers 5*-CAA-GTA-AGT-CTC-GAG-TGT-CTT-
complete SIV-PBj14 gag gene or the gene for the env GGG-3* and 5*-ACC-AGT-TGT-GTT-AAC-CCT-TTT-TAC-
surface protein (SU). Based on the results of these stud-
3*. The DNA primers were chosen to create unique XhoI
ies, we concluded that poliovirus replicons can be used
(5*) and HpaI (3*) restriction sites. For PCR, 30 cycles of
to express proteins which retain their physical features
amplification were performed as follows: 1 min at 947, 1and are discussed with respect to the future use in a
min at 377, and 3 min at 727. Following amplification, thevaccine/challenge model with SIV-PBj14.
DNA fragments were digested with XhoI and HpaI, and
MATERIALS AND METHODS the band was isolated. The fragments were then ligated
into the plasmid containing the poliovirus cDNA that hadUnless otherwise noted, all chemicals and reagents
were purchased from Sigma Chemical Company. The been restricted with XhoI and SnaBI using standard tech-
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FIG. 1. Poliovirus replicons that contain the complete gag and env SU genes of SIV-PBj14. (A) Plasmid pT7-IC that contains a complete poliovirus
infectious cDNA clone; the nucleotide numbering is taken from Kitamura et al. (1981). (B) Structure of pT7-IC-SIV-PBj14 Gag. (C) Structure of pT7-
IC-SIV-PBj14 SU. For both the SIV-PBj14 Gag and SU genes, the DNA fragment was inserted into the poliovirus cDNA between nucleotides 943
and 3359 by digesting with XhoI and HpaI, followed by ligation into the poliovirus replicon digested with XhoI and SnaBI restriction enzymes. Boxed
amino acids indicate changes in the sequence from the native Gag and SU proteins (see text).
niques (Sambrook et al., 1989). The final constructs al., 1991). The cultures were harvested 24 hr after trans-
fection by detergent lysis, clarified, overlaid on a 30%were designated pT7-IC-SIV-PBj14 Gag and pT7-IC-SIV-
sucrose cushion (30% sucrose, 30 mM Tris [pH8.0], 1%PBj14 SU.
Triton X-100, and 0.1 mM NaCl), and subjected to centrif-
ugation in an SW55Ti rotor (Beckman) at 55,000 rpm forEncapsidation and serial passage of replicons
1.5 hr. Supernatants were discarded, and the pelletscontaining the SIV-PBj14 gag and env SU genes
were washed in a low-salt buffer (30 mM Tris [pH8.0],
The encapsidation and serial passage of poliovirus 0.1 M NaCl) and recentrifuged as above. The pellets
replicons using VV-P1 has been described previously were resuspended in complete DMEM, designated as
(Porter et al., 1993, 1995). Briefly, HeLa T4 cells were passage 1, and either stored at0707 or used immediately
infected with 10 PFU of V V-P1 per cell. At 2 hr postinfec- for serial passage.
tion, the cells were transfected by the DEAE-dextran For serial passages of the encapsidated replicons,
method with in vitro-transcribed RNA from the plasmids BSC-40 cells were infected with 10–20 PFU of VV-P1 per
cell. After 2 hr, the cells were infected with the passagepT7-IC-SIV-PBj14 Gag or pT7-IC-SIV-PBj14 SU (Choi et
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1 material. Cultures were harvested 24 hr postinfection phosphate-buffered saline. A portion of the pelleted pro-
teins was added to RIPA buffer and Gag-related proteinsby three successive freeze–thaws and were clarified by
centrifugation at 14,000 g for 20 min. The supernatants were immunoprecipitated with serum from an SIV-PBj14-
infected pig-tailed macaque, followed by SDS–PAGE andwere stored at 0707 or used immediately for additional
passages by the same procedure. fluorography. In some instances, the pelleted material
was layered on a linear 20 to 60% sucrose gradient. After
Metabolic labeling and immunoprecipitation of viral centrifugation in an SW41 rotor at 26,000 rpm for 16 hr,
proteins from infected cells 24 equal fractions were collected from the bottom of the
tube. The SIV-PBj14 Gag proteins were immunoprecipi-
Viral proteins were metabolically labeled as described
tated from even-numbered fractions with antiserum spe-
by Porter et al. (1993). Briefly, infected/transfected cells
cific for SIV-PBj14 and were analyzed by SDS–PAGE
or infected cells were starved for 30 min at 5 hr postinfec-
and fluorography. Sucrose densities for odd-numbered
tion by incubation in DMEM minus methionine–cysteine.
fractions were determined by refractometry.
Cultures were labeled for 1 hr with 35S-Translabel, then
processed for immunoprecipitation of viral proteins by
Enzymatic deglycosylation of SIV-PBj14lysis of cells with radioimmunoprecipitation assay (RIPA)
envelope SU proteinbuffer (150 mM NaCl, 10 mM Tris, pH 7.8, 1% Triton X-100,
1% sodium deoxycholate, 0.2% SDS). For [14C]mannose
BSC-40 cells infected with the encapsidated replicon
labeling, cells infected with the encapsidated replicon
expressing SIV-PBj14 SU were metabolically labeled at
were metabolically labeled at 4.5 hr postinfection. Label-
5 hr postinfection for 1 hr. Following immunoprecipitation
ing was done in DMEM minus glucose that was supple-
with serum from an SIV-PBj14-infected pig-tailed ma-
mented with 25 mCi of [14C]mannose (Amersham) per
caque, the bound proteins were eluted from the protein
milliliter for an additional 6.5 hr. Cells were then lysed
A–Sepharose by heating samples for 10 min in denatur-
in RIPA and, following centrifugation at 14,000 g for 10
ing buffer (50 mM Tris, pH 6.8, 5% SDS, 10% b-mercapto-
min to pellet debris, antibodies were added to the super-
ethanol). After cooling, iodoacetamide was added to a
natants, which were then incubated at 47 with rocking
final concentration of 1.0 mM. The eluted proteins were
for 24 hr. The immunoprecipitates were collected by the
deglycosylated by a simultaneous incubation with 4.0
addition of protein A–Sepharose [10% (w/v) in RIPA
mU neuraminidase, 2.5 mU O-glycosidase, and 0.4 U N-
buffer] and incubated at room temperature with rocking
glycosidase F in 20 mM sodium phosphate (pH 7.2) for
for 1 hr. The protein A–Sepharose beads were collected
18 hr at 377. The treated and untreated proteins were
by a brief centrifugation and washed three times with
analyzed by SDS–PAGE and visualized by fluorography.
RIPA buffer. After elution of the bound material by heating
samples to 957 for 10 min in gel sample buffer (50 mM
Tris, pH 6.8, 5% SDS, 0.01% bromophenol blue, 10% b- RESULTS
mercaptoethanol), the proteins were analyzed by SDS –
Construction of poliovirus replicons containing thepolyacrylamide gel electrophoresis (PAGE) followed by
SIV-PBj14 gag and env SU genesfluorography.
To determine if the expressed proteins were secreted
To construct a replicon containing the SIV-PBj14 gag
from the cells, complete medium was added to the cul-
gene, PCR primers were selected to amplify the 1.5-kDa
tures after the 1 hr of metabolic labeling. The next day
cDNA from nucleotides 822 to 2364 (Dewhurst et al.,
media and cells were processed separately for immuno-
1990). The replicon contains the full-length SIV-PBj14 gag
precipitation.
gene fused with the poliovirus VP4 coding region so that
the translational reading frame is maintained betweenDensity gradient analysis of cells expressing
the VP4 protein and the SIV-PBj14 Gag protein (Fig. 1B).SIV-PBj14 Gag
As a result of the cloning, a two-amino-acid change at
positions 2 and 3 at the amino terminus [Leu-Glu (boxed)BSC-40 cells were infected with encapsidated repli-
cons derived from pT7-IC-SIV-PBj14 Gag and, at 5 hr for Ala-Arg in the wild-type protein] and a single-amino-
acid change at the carboxy terminus [Val (boxed) for thepostinfection, the cells were metabolically labeled for 1
hr followed by addition of complete media. Twenty-four stop codon in the wild-type protein] are present. There
will also be eight additional amino acids, Val-Thr-Lys-hours later, the medium was collected, clarified by cen-
trifugation at 1000 g for 5 min, and filtered through a Asp-Leu-Thr-Thr-Tyr, at the carboxy terminus. Based on
our previous studies, we anticipated that the SIV-PBj140.2-mm pore Acrodisc (Gelman Sciences). The clarified
medium was overlaid on a 20% sucrose cushion and Gag protein will be expressed as a VP4-SIV-PBj14 Gag
fusion protein (predicted molecular mass of 59 kDa), assubjected to ultracentrifugation in an SW41 rotor (Sorvall)
at 26,000 rpm for 2 hr. The pellet was resuspended in well as a SIV-PBj14 Gag protein of approximately 55 kDa
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which is released from the VP4-SIV-PBj14 fusion protein
by the catalytic activity of 2Apro (Porter et al., 1995).
In earlier studies, we have found that the inclusion of
the gene encoding a protein with both a signal sequence
and transmembrane region resulted in a non-replication-
competent RNA molecule (Ansardi et al., 1994). The fur-
ther characterization of this feature of the poliovirus repli-
con will be presented in another study (D. C. Porter et FIG. 2. Expression of poliovirus-specific and SIV-PBj14-specific pro-
al., in preparation). For the current studies, we utilized teins in cells infected with replicons that contain the SIV-PBj14 gag
and env SU genes. Cells were infected with virus stocks at passagePCR to amplify the SIV-PBj14 env SU gene from nucleo-
20. Infected cells were metabolically labeled and cell lysates weretides 6357 to 7952 (Dewhurst et al., 1990). Protein expres-
incubated with the indicated antibodies. The immunoprecipitated pro-
sion from this replicon would result in the synthesis of teins were analyzed by SDS–PAGE and fluorography. (A) Cell lysates
a VP4-SIV-PBj14 SU fusion protein which would be pro- were incubated with anti-3Dpol antibodies to assay for poliovirus-spe-
cessed by the 2Apro in trans. We expected a two-amino- cific protein expression. (B) Proteins immunoprecipitated from cell ly-
sates with serum from an SIV-PBj14-infected pig-tailed macaque. Theacid change at positions 2 and 3 at the amino terminus
orders of the samples for both A and B are as follows: Lane 1, mock-[Leu-Glu (boxed) for Met-Gly in the wild-type protein] and
infected cells; lane 2, VV-P1-infected cells; lane 3, vIC-SIV-PBj14 Gag-
a single-amino-acid change at the carboxy terminus [Val infected cells; lane 4, vIC-SIV-PBj14 SU-infected cells. The molecular
(boxed) for Arg in the wild-type protein]. There will also mass markers and SIV-PBj14 Gag and SU proteins are indicated.
be eight additional amino acids, Val-Thr-Lys-Asp-Leu-
Thr-Thr-Tyr, at the carboxy terminus (Fig. 1C). The pre-
a protein migrating at a molecular mass of 55 to 60 kDadicted molecular mass of the VP4-SIV-PBj14 SU protein
that corresponded to SIV-PBj14 Gag. Two proteins wereis 70 kDa, while that of the 2Apro processed envelope is
immunoprecipitated from lysates infected with vIC-SIV-63 kDa. Since the SIV-PBj14 SU protein still contains an
PBj14 SU. One of these proteins migrated at a molecularintact signal sequence, but no membrane anchor do-
mass consistent with that for the unglycosylated form ofmain, we expected this protein to be translocated
the SIV-PBj14 SU protein (approximately 60 kDa). A sec-through the secretory pathway and secreted from the
ond protein migrated considerably slower in the SDS–cell.
polyacrylamide gels. These results demonstrated that
RNAs encoding the full-length SIV-PBj14 gag gene or the
Expression of SIV-PBj14 Gag and envelope SU SIV-PBj14 env SU gene expressed both poliovirus- and
proteins from poliovirus replicons SIV-PBj14-specific proteins and were encapsidated in
the presence of VV-P1.In vitro transcription was utilized to generate RNA from
pT7-IC-SIV-PBj14 Gag or pT7-IC-SIV-PBj14 SU, which
Further characterization of SIV-PBj14 Gag protein
was transfected into cells to demonstrate that the RNAs
expressed from vIC-SIV-PBj14 Gag
were replication competent (data not shown). In a previ-
ous study, we described a procedure for the encapsida- One of the inherent features of the Gag protein of both
SIV and HIV is its capacity to form virus-like particlestion of poliovirus replicons using a recombinant vaccinia
virus, VV-P1, which expresses the P1 capsid precursor when expressed in the absence of the pol or env gene
(Gheysen et al., 1989; Go¨ttlinger et al., 1989; Park and(Porter et al., 1993). For these studies, cells were infected
with VV-P1, followed by transfection with RNA derived Morrow, 1992). To determine whether the Gag protein
expressed from vIC-SIV-PBj14 Gag would also retain thisfrom in vitro transcription of pT7-IC-SIV-PBj14 Gag or
pT7-IC-SIV-PBj14 SU. A total of 20 serial passages in the feature, a pulse–chase analysis was performed in which
the cells and media were analyzed for the presence ofpresence of VV-P1 was used to generate stocks of the
encapsidated replicons, which will be referred to as vIC- the SIV-PBj14 Gag proteins. A protein with a molecular
mass of 55 kDa was immunoprecipitated from cells la-SIV-PBj14 Gag and vIC-SIV-PBj14 SU. For the analysis
of both poliovirus- and SIV-PBj14-specific proteins, the beled for 1 hr (pulse period); increasing the chase peri-
ods for 2 and 4 hr resulted in decreased intracellularstocks of encapsidated replicons were used to infect
BSC-40 cells. Following metabolic labeling, the lysate levels of the 55-kDa protein. Analysis of the media from
these infected cells revealed that the 55-kDa SIV-PBj14from cells infected with vIC-SIV-PBj14 Gag or vIC-SIV-
PBj14 SU were incubated with anti-3Dpol to detect the Gag protein was present in increasing amounts during
the longer chase periods (data not shown). To determinepoliovirus 3CD protein (Fig. 2A). To determine whether
SIV-PBj14-specific proteins were also expressed, the cell if the SIV-PBj14 Gag proteins were released from the
cells as virus-like particles, a sucrose density-gradientextracts were immunoprecipitated with serum obtained
from a pig-tailed macaque infected with SIV-PBj14 (Fig. analysis was done. The media from metabolically labeled
cells were subjected to ultracentrifugation to pellet any2B). In cells infected with vIC-SIV-PBj14 Gag, we detected
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strated that the expression of the SIV-PBj14 Gag protein
using poliovirus replicons leads to the intracellular syn-
thesis of a 55-kDa protein which is transported and re-
leased from cells, probably as a virus-like particle.
Characterization of SIV-PBj14 SU expressed
from vIC-SIV-PBj14 SU
Infection of cells with the encapsidated replicon vIC-
SIV-PBj14 SU, followed by metabolic labeling and immu-
noprecipitation with serum from an SIV-PBj14-infected
pig-tailed macaque, resulted in the expression of two
SIV-PBj14 envelope-related proteins. One protein had a
molecular mass of approximately 63 kDa which corre-
sponded to the size predicted for the unglycosylated SIV-
PBj14 SU. A second protein which migrated considerably
slower in SDS–polyacrylamide gels was also immuno-
precipitated (Fig. 2B). To further characterize the larger
molecular mass protein, enzymatic deglycosylation of
proteins was performed (Fig. 4A). After enzyme treatment,
a decrease in the apparent molecular mass of this pro-
tein was observed. The protein, however, did not migrate
at a molecular mass consistent with that of a completely
deglycosylated protein, approximately 63 kDa. Rather,FIG. 3. Sucrose density-gradient analysis of virus-like particles re-
leased from cells infected with vIC-SIV-PBj14 Gag. After infection and the molecular mass was approximately 120 kDa, consis-
overnight pulse chase, the media from cells infected with vIC-SIV-PBj14
Gag or vVKI-infected cells were centrifuged to pellet released virus.
Following immunoprecipitation with specific antibodies the plasmid
proteins were analyzed by SDS –PAGE and fluorography. (A) Lane 1,
pelleted material from cells infected with vIC-SIV-PBj14 Gag; lane 2,
pelleted material from cells infected with the recombinant vaccinia virus
vVKI, which contains the gag and pol genes of HIV-1 and expresses the
Pr55gag which is processed to the capsid protein (denoted as p24). In
some instances, the pellet was layered on a linear 20 to 60% sucrose
gradient. Following centrifugation, 24 equal fractions were collected
starting from the bottom of the tube. The proteins were immunoprecipi-
tated from even-numbered fractions using (B) sera from an SIV-PBj14-
infected pig-tailed macaque or (C) anti-HIV-Gag. The immunoprecipi-
tated proteins were analyzed by SDS–PAGE and fluorography. (B) Pro- FIG. 4. Characterization of SIV-PBj14 protein expressed from the
teins immunoprecipitated from sucrose density-gradient fractions of replicon. (A) Enzymatic deglycosylation of the SIV-PBj14 envelope SU
material pelleted from the media of cells infected with vIC-SIV-PBj14 protein. Cells infected with vIC-SIV-PBj14 SU and, as controls, unin-
Gag. (C) Proteins immunoprecipitated from sucrose density-gradient fected cells or cells infected with VV-gp160 were metabolically labeled.
fractions of material pelleted from the media of cells infected with vVK1. Proteins were immunoprecipitated with serum from a SIV-PBj14-in-
The molecular mass markers, SIV-PBj14 Gag, and HIV-1 capsid (p24) fected pig-tailed macaque or with antibodies to HIV-1 envelope. The
are indicated. bound proteins were eluted from the protein A–Sepharose and degly-
cosylated. The treated and untreated proteins were analyzed by SDS–
PAGE and fluorography. The designations of the samples are as fol-
virus-like particles, followed by fractionation on sucrose lows: Cells, extracts prepared from uninfected cells; PBj, cells infected
with vIC-SIV-PBj14 SU; HIV, cells infected with VV-gp160. Lanes 1, 3,gradients (Fig. 3) (Park and Morrow, 1993). Analysis of
and 5, untreated proteins; lanes 2, 4, and 6, proteins treated with thethe even-numbered fractions by immunoprecipitation
deglycosidases. The molecular mass markers are indicated. The highwith serum from an SIV-PBj14-infected pig-tailed ma-
molecular mass SIV-PBj14 SU protein expressed from the replicon is
caque revealed the presence of the 55-kDa SIV-PBj14 noted by an arrow in lane 3; the deglycosylated protein is noted by an
Gag protein. This protein was immunoprecipitated from arrow in lane 4. (B) Immunoprecipitation of SIV-PBj14 SU protein from
[14C]mannose-labeled infected-cell extracts. HeLa T4/ cells were mockfractions which had densities similar to that of HIV-1
infected (lane 1) or infected with vIC-SIV-PBj14 Gag (lane 2) or vIC-SIV-particles released from cells infected with a recombinant
PBj14 SU (lane 3) followed by metabolic labeling with [14C]mannose.vaccinia virus that expresses the HIV-1 gag and pol
Following immunoprecipitation with sera from an SIV-PBj14-infected
genes (vVK1) (Fig. 3A). Previous studies showed that in- pig-tailed macaque, the proteins were separated in SDS–polyacryl-
fection of cells with vVK1 results in the release of virus amide gels followed by fluorography. The molecular mass markers are
as indicated. The SIV-PBj14-SU protein is noted by an arrow in lane 3.particles (Karacostas et al., 1989). These results demon-
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tent with that of an SU protein dimer. Several smaller
SIV-PBj14 envelope-related proteins were also immuno-
precipitated. It is possible these proteins are proteolytic
fragments of the SIV-PBj14 envelope SU protein. As a
control, we performed an identical enzyme treatment of
the gp160 protein immunoprecipitated from cells infected
with a recombinant vaccinia virus that expresses the HIV-
1 envelope protein (VV-gp160). In this case, the deglyco-
sylated HIV-1 gp160 migrated at approximately 96 kDa,
which is consistent with the size of the nonglycosylated
HIV-1 envelope protein. These results demonstrated that
some of the SIV-PBj14 SU protein expressed from the FIG. 5. Secretion of SIV-PBj14 SU from cells infected with vIC-SIV-
PBj14 SU. Infected cells were metabolically labeled at 4.5 hr postinfec-replicon must undergo translocation into the ER with sub-
tion, followed by overnight incubation, at which time the media andsequent glycosylation. To further substantiate that the
cells were processed separately for immunoprecipitation. The proteinsSIV-PBj14 SU protein expressed in replicon-infected cells
immunoprecipitated from the cells or media are presented. For the
was glycosylated, we metabolically labeled replicon-in- samples in lanes 1, 2, 3, 4, and 6, 7, 8, 9, serum from a SIV-PBj14-
fected cells with [14C]mannose, followed by immunopre- infected pig-tailed macaque was used; the samples in lanes 5 and
10 were immunoprecipitated with anti-HIV-1 envelope antibodies. Thecipitation with sera from a SIV-PBj14-infected pig-tailed
order of the samples for both the cells and the media are as follows:macaque (Fig. 4B). Only the larger molecular mass pro-
Lane 1, mock-infected; lane 2, VV-P1-infected; lane 3, vIC-SIV-PBj14tein was immunoprecipitated from the cells infected with
Gag-infected; lane 4, vIC-SIV-PBj14 SU-infected; lane 5, VV-gp160-in-
the replicon encoding SIV-PBj14 SU. We did not immuno- fected. The molecular mass markers are noted. The SIV-PBj14 Gag
precipitate the 63-kDa SIV-PBj14 SU protein, which is (lane 8) and SIV-PBj14 SU (lanes 9) proteins present in the media after
overnight incubation are noted by arrows.consistent with the notion that this protein is the nongly-
cosylated SIV-PBj14 SU. Furthermore, we did not detect
the same molecular mass protein from control (nonin-
nant vaccinia virus, VV-P1, which expresses the poliovi-fected cells) or cells infected with replicons which en-
rus P1 protein. Infection of cells with encapsidated repli-code SIV-PBj14 Gag. Taken together, the results of the
cons containing the SIV-PBj14 gag gene resulted in theenzymatic deglycosylation studies and metabolic label-
production of a 55-kDa protein which was probably re-ing with [14C]mannose provide strong evidence that some
leased from cells as a virus-like particle. Replicons con-of the SIV-PBj14-SU expressed from the replicon was
taining the SIV-PBj14 env SU gene were also replicationglycosylated.
competent and were encapsidated when passaged inSince the SIV-PBj14 SU protein does not contain a
the presence of VV-P1. Infection of cells with these en-series of amino acids which constitute a membrane an-
capsidated replicons resulted in the production of twochor, the SU protein should be present in the culture
proteins: one protein had a molecular mass consistentmedia if it is correctly folded and glycosylated (Doms et
with an unglycosylated SU protein, while a second pro-al., 1993; Gething and Sambrook, 1992). To determine if
tein was glycosylated and had a molecular mass in ex-this was the case for the SIV-PBj14 SU expressed from
cess of 160 kDa. Following pulse–chase analysis, ana poliovirus replicon, the media from replicon-infected
envelope protein which had a molecular mass consistentcells was analyzed. A protein with a molecular mass of
with the SIV-PBj14 SU protein (110–130 kDa) was de-110–130 kDa, which is consistent with that for the SU
tected in the media of replicon-infected cells.protein of SIV, was immunoprecipitated using serum from
The expression of the SIV-PBj14 Gag protein from po-an infected pig-tailed macaque (Fig. 5) (Dewhurst et al.,
liovirus replicons was similar to that observed for the1990; Gallaher et al., 1995). These results suggested that
expression of HIV-1 Gag using a poliovirus replicon (Por-some of the SIV-PBj14 SU expressed from the replicon
ter et al., 1995). In both cases, we observed the expres-had indeed undergone correct protein folding and glyco-
sion of a VP4–Gag precursor protein, which was subse-sylation prior to release from cells.
quently processed into a mature Gag protein. The proteo-
lytic processing of VP4–SIV-PBj14 Gag by 2Apro in transDISCUSSION
was rapid since only low levels of the VP4–Gag fusion
protein were seen during labeling times of 1–2 hr. BothIn this article, we described the construction and char-
the SIV-PBj14 Gag and the HIV-1 Gag were detected inacterization of poliovirus replicons that contain the com-
abundant amounts intracellularly and were released fromplete gag and env SU genes for the simian immunodefi-
infected cells. Using sucrose gradients, we found thatciency virus, SIV-PBj14. These recombinant poliovirus
both the SIV-PBj14 Gag and the HIV-1 Gag expressedRNAs were replication competent and were encapsi-
dated when passaged in the presence of the recombi- from poliovirus replicons sedimented at a density consis-
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tent with that for a virus-like particle. In recent experi- SIV-PBj14 SU protein, which then directs the SU protein
to the ER. In some respects, this process is analogous toments, we have confirmed by electron microscopy that
the HIV-1 Gag forms a virus-like particle; we anticipate the expression of Sindbis virus (Aliperti and Schlesinger,
1987) or Semliki Forest virus (SFV) structural proteinsthe case will be the same for SIV-PBj14 Gag. We also
noted that upon longer exposure of the autoradiogram, (Liljestrom and Garoff, 1991; Melancon and Garoff, 1987).
In SFV, the initial protein product is a fusion protein be-low levels of the VP4–SIV-PBj14 Gag were present in
fractions containing SIV-PBj14 Gag. From a pulse–chase tween the capsid-p62-6K-E1 protein. After the synthesis
of the capsid protein, its autocatalytic activity releasesanalysis, we found the VP4–SIV-PBj14 Gag was present
in the supernatants at earlier times after infection than the capsid from p62, exposing a signal peptide that tar-
gets the translation complex to the ER membrane.the SIV-PBj14 Gag protein. These results indicate that
the release of the SIV-PBj14 Gag protein might be slower Although it was clear from our studies with enzymatic
deglycosylation and [14C]mannose labeling that the SIV-than that of the VP4–SIV-PBj14 Gag. It is possible that
the VP4–SIV-PBj14 Gag protein is efficiently transported PBj14 SU protein expressed from the poliovirus replicon
was glycosylated, the protein had a molecular massout of cells due to myristylation of the poliovirus VP4
protein (Ansardi et al., 1992). The delay in the release of greater than that of the HIV-1 gp160 protein. Character-
ization of this protein by enzymatic deglycosylation re-the SIV-PBj14 Gag might be due to the fact that SIV-
PBj14 Gag, like the HIV-1 Gag, needs to be myristylated vealed a protein with a molecular mass of approximately
120 kDa, rather than the 60-kDa protein expected fromprior to release from cells (Bryant and Ratner, 1990; Go¨t-
tlinger et al., 1989). In support of this explanation, in a the unglycosylated SIV-PBj14 SU. It is possible that the
larger mass form of the SIV-PBj14 SU is actually a dimerrelated study we demonstrated that both the VP4–HIV-
1 Gag protein and the 2Apro processed Gag protein were of the SIV-PBj14 SU protein. Dimers resistant to condi-
tions normally employed in SDS–PAGE of HIV-2 andmyristylated (D. C. Porter et al., submitted). Experiments
are ongoing to further characterize the assembly and SIVmac142 env proteins have been identified in cells in-
fected with these viruses (Rey et al., 1989). As noted byrelease of SIV-PBj14 Gag.
A unique feature of the present study is the demonstra- Rey et al. (1989), the formation of these envelope dimers
is required for the proteins to be transported and pro-tion that poliovirus replicons encoding the signal peptide
of the SIV-PBj14 env SU gene were replication compe- cessed through the Golgi apparatus. Although recent
studies have suggested that poliovirus infection of cellstent. Previous attempts to express the full-length HIV-1
env gene, as well as the full-length gene for another alters the secretory pathway (Doedens and Kirkegaard,
1995), we did detect SIV-PBj14 SU protein of correct mo-glycoprotein, carcinoembryonic antigen, were also un-
successful (Ansardi et al., 1994; D. C. Porter et al., in lecular mass (110–130 kDa) released from infected cells.
The fact that the SIV-PBj14 SU protein expressed frompreparation). These results, as well as those from other
laboratories, lead to the suggestion that signal se- the replicon was secreted provides strong evidence that
some of the SIV-PBj14 SU expressed from the repliconquences in the glycoprotein gene were somehow delete-
rious to poliovirus replication (Alexander et al., 1994; Lu has undergone the appropriate translocation into the ER,
protein folding, glycosylation, and transport through theet al., 1995). In fact, Lu et al. concluded that poliovirus
vectors may not be applicable for the expression of glyco- Golgi apparatus (Doms et al., 1993; Gething and Sam-
brook, 1992). Further studies with additional glycopro-sylated proteins. In order to express SIV-PBj14, we had
to position the SIV-PBj14 SU gene downstream from teins will be required to determine if this situation is
unique to SIV-PBj14.the poliovirus VP4 coding region. Replicons with the
SIV-PBj14 SU gene containing the signal sequence posi- Finally, the results of these studies support the future
use of poliovirus vectors as vaccine vectors. Recent stud-tioned at nucleotide 743, the initiating AUG of the poliovi-
rus polyprotein, were not replication competent (unpub- ies from this laboratory have demonstrated that adminis-
tration of replicons alone resulted in the generation of alished results). Based on our previous studies with SIV-
PBj14 and HIV-1 Gag, we believe the SIV-PBj14 envelope humoral immune response against an expressed protein
(Ansardi et al., 1994; Moldoveanu et al., 1995). Based onSU protein is synthesized from the replicon as a VP4–
SIV-PBj14 SU fusion protein (Porter et al., 1995). Although the results of the present study, it should be possible to
formulate a cocktail vaccine composed of replicons thatit is possible that the complete fusion protein is translo-
cated into the ER, we were unable to immunoprecipitate express SIV-PBj14 Gag and SU and to evaluate whether
immunization with such vectors elicits protective immunethe SIV-PBj14 SU protein expressed from the poliovirus
replicon with the anti-poliovirus capsid antibodies that responses. Infection of pig-tailed macaques with SIV-
PBj14 is an especially attractive model for vaccine effi-recognize the VP4 protein (unpublished results). We be-
lieve therefore, that the VP4–SIV-PBj14 SU fusion protein cacy studies because this lentivirus reliably infects ma-
caques and induces an acute disease syndrome follow-is processed in trans by 2Apro; this processing exposes
the NH2 terminus containing the signal sequence of the ing both parenteral and mucosal exposure (Fultz, 1991).
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sor Pr55gag virus-like particles from recombinant baculovirus-in-Thus, experiments can be designed not only to immunize
fected insect cells. Cell 59, 103–112.and challenge the animals by mucosal routes, but also
Go¨ttlinger, H. G., Sodroski, J. G., and Haseltine, W. A. (1989). Role of
to evaluate prevention of infection or disease (Morrow capsid precursor processing and myristylation in morphogenesis
et al., 1994). and infectivity of human immunodeficiency virus type 1. Proc. Natl.
Acad. Sci. USA 86, 5781–5785.
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